A comparative study of terbinafine versus griseofulvin in 'dry-type' dermatophyte infections.
We conducted a double-blind comparative study of terbinafine, 250 mg twice daily, versus griseofulvin, 500 mg twice daily, for 6 weeks in chronic dermatophyte infections of the feet or hands. All but three patients (total 31) had Trichophyton rubrum infection. At 12-week follow-up, 100% of the terbinafine-treated group were free from infection compared with 45% of those treated with griseofulvin. Therapy in 75% of the terbinafine-treated group and in 35% of those given griseofulvin was rated as effective overall at long-term follow-up, although these differences were not statistically significant. Six months after treatment all nine patients whose skin had cleared with terbinafine therapy remained in remission versus only one of seven patients treated with griseofulvin. None of the patients in either group experienced serious adverse effects.
Hay
R J
RJ
Mycology Unit, St. Thomas Hospital, London, U.K.
Logan
R A
RA
Moore
M K
MK
Midgely
G
G
Clayton
Y M
YM
D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002908:Chronic Disease; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D005533:Foot Dermatoses / Q000188:drug therapy; D006118:Griseofulvin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006229:Hand Dermatoses / Q000188:drug therapy; D006801:Humans; D008297:Male; D009260:Nail Diseases / Q000175:diagnosis / Q000188:drug therapy; D009281:Naphthalenes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012008:Recurrence; D000077291:Terbinafine; D014005:Tinea / Q000188:drug therapy* / Q000473:pathology
D000935:Antifungal Agents; D009281:Naphthalenes; D006118:Griseofulvin; D000077291:Terbinafine